|
1
|
Weiss G and Goodnough LT: Anemia of
chronic disease. N Engl J Med. 352:1011–1023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steegmann JL, Sanchez Torres JM, Colomer
R, Vaz A, Lopez J, Jalon I, Provencio M, Gonzalez-Martin A and
Perez M: Prevalence and management of anaemia in patients with
non-myeloid cancer undergoing systemic therapy: A Spanish survey.
Clin Transl Oncol. 15:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Szenajch J, Wcislo G, Jeong JY, Szczylik C
and Feldman L: The role of erythropoietin and its receptor in
growth, survival and therapeutic response of human tumor cells from
clinic to bench-A critical review. Biochim Biophys Acta.
1806:82–95. 2010.PubMed/NCBI
|
|
4
|
Marti HH: Erythropoietin and the hypoxic
brain. J Exp Biol. 207:3233–3242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Y, Zhang H, Liu Y, Li P, Cao Z and
Cao Y: Erythropoietin (EPO) protects against high glucose-induced
apoptosis in retinal ganglional cells. Cell Biochem Biophys.
71:749–755. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pezeshki Z, Nematbakhsh M, Mazaheri S,
Eshraghi-Jazi F, Talebi A, Nasri H, Safari T, Mansouri A and
Ashrafi F: Estrogen abolishes protective effect of erythropoietin
against cisplatin-induced nephrotoxicity in ovariectomized rats.
SRN Oncol. 2012:8903102012.
|
|
7
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Candelaria M, Cetina L and Dueñas-Gonzalez
A: Anemia in cervical cancer patients. Implications for iron
supplementation therapy. Med Oncol. 22:161–168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lopez TV, Lappin TR, Maxwell P, Shi Z,
Lopez-Marure R, Aguilar C and Rocha-Zavaleta L: Autocrine/paracrine
erythropoietin signalling promotes JAK/STAT-dependent proliferation
of human cervical cancer cells. Int J Cancer. 129:2566–2576. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aguilar C, Aguilar C, Lopez-Marure R,
Jimenez-Sanchez A and Rocha-Zavaleta L: Co-stimulation with stem
cell factor and erythropoietin enhances migration of c-kit
expressing cervical cancer cells through the sustained activation
of ERK1/2. Mol Med Rep. 9:1895–1902. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamadmad SN and Hohl RJ: Lovastatin
suppresses erythropoietin receptor surface expression through dual
inhibition of glycosylation and geranylgeranylation. Biochem
Pharmacol. 74:590–600. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukada T, Hibi M, Yamanaka Y,
Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, Nakajima K and Hirano
T: Two signals are necessary for cell proliferation induced by a
cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis.
Immunity. 5:449–460. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gu L, Chiang KY, Zhu N, Findley HW and
Zhou M: Contribution of STAT3 to the activation of survivin by
GM-CSF in CD34+ cell lines. Exp Hematol. 35:957–966.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Connor DS, Grossman D, Plescia J, Li F,
Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation
of apoptosis at cell division by p34cdc2 phosphorylation
of survivin. Proc Natl Acad Sci USA. 97:13103131072000. View Article : Google Scholar
|
|
15
|
Wall NR, O'Connor DS, Plescia J, Pommier Y
and Altieri DC: Suppression of survivin phosphorylation on Thr34 by
flavopiridol enhances tumor cell apoptosis. Cancer Res. 63:230–235.
2003.PubMed/NCBI
|
|
16
|
Judd LM, Menheniott TR, Ling H, Jackson
CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of
the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and
in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alural B, Ayyildiz ZO, Tufekci KU, Genc S
and Genc K: Erythropoietin promotes glioblastoma via miRNA-451
suppression. Vitam Horm. 105:249–271. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merkle R, Steiert B, Salopiata F, Depner
S, Raue A, Iwamoto N, Schelker M, Hass H, Wasch M, Bohm ME, et al:
Identification of cell type-specific differences in erythropoietin
receptor signalling in primary erythroid and lung cancer cells.
PLoS Comput Biol. 12:e10050492016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu H, Luo H, Zhang W, Shen Z, Hu X and
Zhu X: Molecular mechanisms of cisplatin resistance in cervical
cancer. Drug Des Devel Ther. 10:1885–1895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding Z, Yang X, Pater A and Tang SC:
Resistance to apoptosis is correlated with the reduced caspase-3
activation and enhanced expression of antiapoptotic proteins in
human cervical multidrug-resistant cells. Biochem Biophys Res
Commun. 270:415–420. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lai SY, Childs EE, Xi S, Coppelli FM,
Gooding WE, Wells A, Ferris RL and Grandis JR:
Erythropoietin-mediated activation of JAK-STAT signaling
contributes to cellular invasion in head and neck squamous cell
carcinoma. Oncogene. 24:4442–4449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi Z, Hodges VM, Dunlop EA, Percy MJ,
Maxwell AP, El-Tanani M and Lappin TR: Erythropoietin-induced
activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways
promotes malignant cell behaviour in a modified breast cancer cell
line. Mol Cancer Res. 8:615–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei S, Luo C, Yu S, Gao J, Liu C, Wei Z,
Zhang Z, Wei L and Yi B: Erythropoietin ameliorates early brain
injury after subarachnoid haemorrage by modulating microglia
polarization via the EPOR/JAK2-STAT3 pathway. Exp Cell Res.
361:342–352. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of STAT3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu W, Jin P and Liu W: Periostin
contributes to cisplatin resistance in human non-small cell lung
cancer A549 cells via activation of Stat3 and Akt and upregulation
on survivin. Cell Physiol Biochem. 38:1199–1208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan Y and Chen J: Clinicopathological
significance of survivin expression in patients with cervical
cancer: A systematic meta-analysis. Bioengineered. 8:511–523. 2017.
View Article : Google Scholar : PubMed/NCBI
|
